medigraphic.com
ISSN 0210-5187 (Electronic)

2020, Number 1

<< Back Next >>

Med Cutan Iber Lat Am 2020; 48 (1)

Atypical fibroxanthomas: study in 52 cases

Pereyra RJJ, Parra MN, Domínguez CJ, Corbis Llopis R, Conejo-Mir J

Language: Spanish
References: 27
Page: 41-46
PDF size: 315.74 Kb.


ABSTRACT

Introduction: Atypical fibroxanthoma (FXA) is a superficial fibrohistiocytic tumor of intermediate malignancy, predominantly in elderly men in photoexposed areas. The objective of this work is to describe the demographic and clinical characteristics of FXA of patients treated in a third level hospital. Material and methods: Observational, descriptive, retrospective study where patients with histological diagnosis of FXA were included between the years 2004-2017. The sample was divided into two periods: 2004-2010 and 2011-2017 to contrast differences between periods. Clinical characteristics were collected (sex, age of the patient, history of skin cancer, location and size of the lesion). Results: 52 patients, 41 men and 11 women were included, with a mean age of 78.8. The most frequent location was the scalp. Three patients presented local recurrence. A 47.6% increase was observed in the cases of the second study period. Conclusion: FXA is a tumor with little tendency to recur. An increase in the number of FXA has been observed in recent years.


REFERENCES

  1. Helwig E. Atypical fibroxanthoma. Tex State J Med. 1963; (59): 664.

  2. Kempson RL, McGavran MH. Atypical fibroxanthomas of the skin. Cancer. 1964; 17: 1463-1471. http://www.ncbi.nlm.nih.gov/pubmed/14223763. Accessed August 14, 2018.

  3. Miller K, Goodlad JR, Brenn T. Pleomorphic dermal sarcoma: adverse histologic features predict aggressive behavior and allow distinction from atypical fibroxanthoma. Am J Surg Pathol. 2012; 36 (9): 1317-1326. doi: 10.1097/PAS.0b013e31825359e1.

  4. Hussein MRA. Atypical fibroxanthoma: new insights. Expert Rev Anticancer Ther. 2014; 14 (9): 1075-1088. doi: 10.1586/14737140.2014.924401

  5. Tolkachjov SN, Schmitt AR, Muzic JG, Weaver AL, Baum CL. Incidence and clinical features of rare cutaneous malignancies in olmsted County, Minnesota, 2000 to 2010. Dermatologic Surg. 2017; 43 (1): 116-124. doi: 10.1097/DSS.0000000000000936.

  6. Iorizzo LJ, Brown MD. Atypical fibroxanthoma: a review of the literature. Dermatol Surg. 2011; 37 (2): 146-157. doi: 10.1111/j.1524-4725.2010.01843.x.

  7. Brenn T. Pleomorphic dermal neoplasms: a review. Adv Anat Pathol. 2014; 21 (2): 108-130. doi: 10.1097/PAP.0000000000000009.

  8. Gru AA, Santa Cruz DJ. Atypical fibroxanthoma: a selective review. Semin Diagn Pathol. 2013; 30 (1): 4-12. doi: 10.1053/j.semdp.2012.01.001.

  9. Weedon D. Tumors and tumor-like roliferations of fibrous and related tissues. In: Skin Pathology. 2nd ed. London: Churchill Livingstone; 2002, pp. 917-954.

  10. Cordero M, Sorgentini C, Allevato MA, Cabrera H, Juarez M. Fibroxantoma atípico. Act Ter Dermatol. 2007; 30: 110-113.

  11. Diaz-Cascajo C, Weyers W, Borghi S. Pigmented atypical fibroxanthoma: a tumor that may be easily mistaken for malignant melanoma. Am J Dermatopathol. 2003; 25 (1): 1-5. http://www.ncbi.nlm.nih.gov/pubmed/12544091. Accessed August 14, 2018.

  12. Tolkachjov SN, Kelley BF, Alahdab F, Erwin PJ, Brewer JD. Atypical fibroxanthoma: systematic review and meta-analysis of treatment with mohs micrographic surgery or excision. J Am Acad Dermatol. 2018; 79 (5): 929-934.e6. doi: 10.1016/j.jaad.2018.06.048.

  13. Ziemer M. Atypical fibroxanthoma. J Dtsch Dermatol Ges. 2012; 10 (8): 537-550. doi: 10.1111/j.1610-0387.2012.07980.x.

  14. Neil CA, Carlson SK, Macinnis C, Taylor JR, Battaglia T, LaMar WL et al. Clear cell atypical fibroxanthoma: a clinicopathologic study. J Cutan Pathol. 2002; 29 (6): 374-381. http://www.ncbi.nlm.nih.gov/pubmed/12135470. Accessed August 14, 2018.

  15. Dei Tos AP, Maestro R, Doglioni C, Gasparotto D, Boiocchi M, Laurino L et al. Ultraviolet-induced p53 mutations in atypical fibroxanthoma. Am J Pathol. 1994; 145 (1): 11-17. http://www.ncbi.nlm.nih.gov/pubmed/8030743. Accessed August 14, 2018.

  16. Sakamoto A, Oda Y, Itakura E, Oshiro Y, Nikaido O, Iwamoto Y et al. Immunoexpression of ultraviolet photoproducts and p53 mutation analysis in atypical fibroxanthoma and superficial malignant fibrous histiocytoma. Mod Pathol. 2001; 14 (6): 581-588. doi: 10.1038/modpathol.3880354.

  17. Beer TW, Drury P, Heenan PJ. Atypical fibroxanthoma: a histological and immunohistochemical review of 171 cases. Am J Dermatopathol. 2010; 32 (6): 533-540. doi: 10.1097/DAD.0b013e3181c80b97.

  18. Gómez de la Fuente E, Sols M, Pinedo F, Álvarez-Fernández JG, Vicente FJ, Naz E et al. Atypical fibroxanthoma. Clinical/pathological study of 10 cases. Actas Dermosifiliogr. 2005; 96 (3): 153-158. http://www.ncbi.nlm.nih.gov/pubmed/16476356. Accessed August 14, 2018.

  19. Sánchez HC, Díez RE, Bélmar FP, Vergara SA, Jiménez BE, Cuevas SJ, Eusebio ME. Atypical fibroxanthoma. a clinicopathological and immunohistochemical study of ten cases. Med Cutan Iber Lat Am. 2008; 36 (2): 66-71.

  20. Wollina U, Schönlebe J, Ziemer M, Friedling F, Koch A, Haroske G, Kaatz M et al. Atypical fibroxanthoma: a series of 56 tumors and an unexplained uneven distribution of cases in southeast Germany. Head Neck. 2015; 37 (6): 829-834. doi: 10.1002/hed.23673.

  21. Mahalingam S, Shah A, Stewart A. Atypical fibroxanthoma: a case series and review of literature. Auris Nasus Larynx. 2015; 42 (6): 469-471. doi:10.1016/j.anl.2015.04.001.

  22. Sakamoto A. Atypical fibroxanthoma. Clin Med Oncol. 2008; 2: 117-127. http://www.ncbi.nlm.nih.gov/pubmed/21892274. Accessed August 14, 2018.

  23. Helwig EB, May D. Atypical fibroxanthoma of the skin with metastasis. Cancer. 1986; 57 (2): 368-376. http://www.ncbi.nlm.nih.gov/pubmed/3942970. Accessed August 14, 2018.

  24. Koch M, Dimmler A, Alexiou C. Recurrent and metastasizing atypical fibroxanthoma. HNO. 2008; 56 (10): 1046-1051. doi:10.1007/s00106-007-1636-3.

  25. Kargi E, Güngör E, Verdi M, Kuiaçogiu S, Erdogan B, Alli N et al. Atypical fibroxanthoma and metastasis to the lung. Plast Reconstr Surg. 2003; 111 (5): 1760-1762. http://www.ncbi.nlm.nih.gov/pubmed/12655231. Accessed August 14, 2018.

  26. Gordon R. Skin cancer: an overview of epidemiology and risk factors. Semin Oncol Nurs. 2013; 29 (3): 160-169. doi: 10.1016/j.soncn.2013.06.002.

  27. Coggshall K, Tello TL, North JP, Yu SS. Merkel cell carcinoma: an update and review part 1. pathogenesis, diagnosis, and staging. J Am Acad Dermatol. J Am Acad Dermatol. 2018; 78 (3): 433-442. doi: 10.1016/j.jaad.2017.12.001.




2020     |     www.medigraphic.com